Medicare Enrolled
Dr. Abubakr Bajwa, M.D.
Pulmonary Disease · Jacksonville, FL
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bajwa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bajwa?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bajwa
Dr. Abubakr Bajwa is a pulmonary disease specialist in Jacksonville, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bajwa performed 1,547 Medicare services across 1,360 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bajwa received a total of $478,055 from 35 pharmaceutical and/or device companies across 675 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bajwa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 39% volume in FL
$478,055 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 93141 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗1,547
Medicare services
Top 39% in FL for pulmonary disease
1,360
Unique beneficiaries
$66
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~77 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
363 | $85 | $346 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
161 | $44 | $310 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
153 | $20 | $212 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
136 | $42 | $317 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
114 | $62 | $244 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
77 | $122 | $582 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
63 | $140 | $714 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
53 | $30 | $339 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
35 | $7 | $91 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $97 | $425 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
33 | $9 | $195 |
| New patient office visit, complex (60-74 min) | 31 | $171 | $882 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
28 | $89 | $372 |
| Computer-assisted navigation of lung airways This procedure uses computer technology to guide an endoscope through the airways of the lungs for precise navigation. |
24 | $78 | $305 |
| Bronchoscopy with ultrasound and growth treatment A procedure using a flexible tube with a camera and ultrasound to examine the lung airways and treat any growths found. |
24 | $54 | $214 |
| Endoscopic needle biopsy of windpipe, airway, or lung A procedure where a needle is inserted through an endoscope to collect tissue samples from the windpipe, airway, or lung. |
23 | $130 | $590 |
| Inhalation treatment for pneumonia Administration of medication via inhalation to treat pneumonia. This procedure involves delivering therapeutic agents directly to the lungs. |
23 | $24 | $265 |
| Inhaled pentamidine, 300 mg Administration of FDA-approved pentamidine isethionate via a nebulizer or DME device. The dose is measured in 300 mg units. |
22 | $69 | $447 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
20 | $78 | $388 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $106 | $441 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing, airflow, and physical effort during sleep. |
17 | $38 | $501 |
| Lung airway sensitivity test A test used to measure the sensitivity of the airways in the lungs. |
16 | $48 | $364 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $90 | $439 |
| Health risk assessment administration and interpretation This procedure involves administering a health risk assessment to a patient and interpreting the results. |
13 | $2 | $13 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
13 | $65 | $261 |
| Other lung procedure A medical service or procedure performed on the lung that does not fall under other specific categories. |
12 | $56 | $388 |
| Nitric oxide gas level test A test that measures the level of nitric oxide gas in the body. |
12 | $14 | $133 |
| Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | 12 | $1 | $782 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$478,055
Total received (2018-2024)
Avg $68,294/year across 7 years
Top 1% in FL for pulmonary disease
35
Companies
675
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$431,273 (90.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$38,342 (8.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,440 (1.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,160
2023
$53,203
2022
$85,029
2021
$114,884
2020
$61,053
2019
$87,960
2018
$69,765
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
United Therapeutics Corporation
$171,041
Boehringer Ingelheim Pharmaceuticals, Inc.
$124,310
Actelion Pharmaceuticals US, Inc.
$67,299
Intuitive Surgical, Inc.
$65,085
Insmed, Inc.
$19,579
Bayer HealthCare Pharmaceuticals Inc.
$14,251
AstraZeneca Pharmaceuticals LP
$8,768
Gilead Sciences, Inc.
$2,052
Pulmonx Corporation
$1,749
GlaxoSmithKline, LLC.
$1,216
Bayer Healthcare Pharmaceuticals Inc.
$578
Genentech USA, Inc.
$545
Sunovion Pharmaceuticals Inc.
$230
Inspire Medical Systems, Inc.
$216
Merck Sharp & Dohme LLC
$209
Novartis Pharmaceuticals Corporation
$124
Vapotherm Inc
$123
Shire North American Group Inc
$95
Phadia US Inc.
$84
Ambu Inc.
$80
Mallinckrodt LLC
$60
Grifols USA, LLC
$42
Mylan Specialty L.P.
$39
Merck Sharp & Dohme Corporation
$37
Mallinckrodt Enterprises LLC
$37
GENZYME CORPORATION
$31
E.R. Squibb & Sons, L.L.C.
$30
Allergan Inc.
$25
INTUITIVE SURGICAL, INC.
$23
Regeneron Healthcare Solutions, Inc.
$21
SANOFI-AVENTIS U.S. LLC
$17
Boston Scientific Corporation
$17
Sandoz Inc.
$15
Circassia Pharmaceuticals Inc
$14
EKOS Corporation
$14
Top 3 companies account for 75.9% of total payments
Associated products mentioned in payments ›
ACTHAR · ALAIR · ANORO · AVYCAZ · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · CHARTIS CATHETER · DA VINCI SP · DUPIXENT · Da Vinci Surgical System · EKOSONIC · ELIQUIS · Esbriet · FASENRA · GLASSIA · INSPIRE · ImmunoCAP · LONHALA MAGNAIR · Letairis · NONE · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · Precision Flow · Prolastin-C · Pulmonx Endobronchial Valve EBV · REMODULIN · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TRELEGY ELLIPTA · TREPROSTINIL · TUDORZA PRESSAIR · TYVASO · UPTRAVI · UTIBRON · Utibron · WINREVAIR · XOLAIR · Xolair · Yupelri · ZEPHYR DELIVERY CATHETER · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (90%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in FL.
Equivalent to $30,902 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
63
Per 100K population
6.3
County median income
$68,447
Nearest hospital
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Bajwa is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 1% of FL peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Bajwa experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Bajwa performed 363 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bajwa receive payments from pharmaceutical companies?
Yes. Dr. Bajwa received a total of $478,055 from 35 companies across 675 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bajwa's costs compare to other pulmonary diseases in Jacksonville?
Dr. Bajwa's average Medicare payment per service is $66. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bajwa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Jacksonville
Browse pulmonary diseases in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in FL
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in FL
Which FL pulmonary diseases receive the most from drug and device companies.
By company
United Therapeutics Corporation Payments to Doctors
See all physicians who received payments from United Therapeutics Corporation.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology